The Middle-East & Africa Biomaterials Market was worth USD 8626.96 Million in 2023 and is estimated to be growing at a CAGR of 13.89%, to reach USD 16530.5 Million by 2028. The use of medical plastic, stainless steel /titanium metal replacement implant materials for medical purposes is being affected by biocompatibility issues, in addition to the demand for superior implant mechanical performance. For this, the manufacturers are looking towards more effective and companionable materials.
Increased use of biomaterials is mainly attributed to the research efforts in medical technology for the efficient functionality of medical implants. In addition, an increase in government funding and availability of new technologies such as hydrogen scaffolding and decellularized dermal matrixes for grafting are some of the factors driving the growth of the Middle-East & Africa biomaterials market. Furthermore, due to the increasing number of geriatric patients, the demand for the usage of biomaterials in cardiology, wound healing, neurology, and plastic surgery is also on the rise. Besides, it will contribute to the market is growing at a healthy rate throughout the forecast period.
However, adverse reactions to biomaterial implants, inflammation and fracture issues, high cost associated with, and difficulties in manufacturing are the major factors off-putting the growth of the Middle-East & Africa biomaterials market.
This research report on the MEA biomaterials market has been segmented and sub-segmented the European biomaterials market into the following categories:
By Material Type:
KEY MARKET PLAYERS:
Some of the key players in the Middle-East & Africa biomaterials market include Royal DSM, Zimmer Biomet Holdings, Inc., Wright Medical Technology, Inc., Corbion N.V., Berkeley Advanced Biomaterials, Bayer AG, Carpenter Technology Corporation, Evonik Industries AG, Covalon Technologies Ltd., BASF SE, Invibio Ltd., Inc., CAM Bioceramics BV, and Collagen Matrix, Inc.
While existing players operating in the Middle East & Africa are trying to expand their product portfolio and increase growth, few companies are trying to enter the market through acquisitions to capitalize on the growing opportunities.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org